Trilliant’s Corporate Commitment to Sustainability Reinforced with Certifications, Awards
28.8.2023 02:00:00 EEST | Business Wire | Press release
Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, continues to focus on its commitment to sustainability for its customers and the company with new recertifications, awards and assessments.
Trilliant previously announced its Integrated Management System was recertified to ISO 9001:2015 and ISO 14001:2015. Recently, DEKRA Audits has also recertified Trilliant in the following areas, solidifying Trilliant’s commitment to sustainable business operations:
- ISO 27001:2013 standard for information security management systems (ISMS): ISO 27001 is the world's best-known standard for ISMS and defines requirements an ISMS must meet. The standard provides companies with guidance for establishing, implementing, maintaining, and continually improving an information security management system. Conformity with ISO/IEC 27001 means that an organization or business has put in place a system to manage risks related to the security of data owned or handled by the company, and that this system respects all the best practices and principles enshrined in this International Standard.
- ISO 45001:2018 standard for occupational health and safety (OH&S) management: ISO 45001:2018 specifies requirements for an OH&S management system. It gives guidance for its use to enable organizations to provide safe and healthy workplaces by preventing work-related injury and ill health, as well as by proactively improving its OH&S performance.
In June 2023, Trilliant was recertified for the ECORESPONSIBLE™ Certification, progressing to Level #2 (Performance). This certification in sustainable development management is part of an ongoing four-level improvement process, designed to help organizations improve their overall performance in economic, environmental, social and governance terms. By making strategic decisions regarding sustainable development through their ECORESPONSIBLE practices, organizations show their tangible contribution to sustainable development. In doing so, they reduce their ecological impact and improve their value chain.
Trilliant is also the recipient of a 2022 EcoVadis Silver medal and placed in the top 19 percent within its industry. EcoVadis has grown to become the world’s largest and most trusted provider of business sustainability ratings, creating a global network of more than 100,000+ rated companies. EcoVadis medals recognize companies that have completed the EcoVadis assessment process and demonstrated a relatively strong management system that addresses sustainability criteria, as outlined in the EcoVadis methodology. Companies must also meet specific licensing and eligibility criteria.
Trilliant’s office in Granby, Québec, was recently recognized by the City of Granby with an Environmental Recognition Award. This awards honors citizens, non-profit organizations, businesses, industries and educational institutions of the City of Granby who have made an outstanding contribution to the community and its reputation through their commitment and achievements in environmental and sustainable development matters. Trilliant was honored in the Sustainable Industry category for its ECORESPONSIBLE™ certification.
Sustainability: A key pillar of Trilliant’s strategy
Trilliant understands that not only is sustainability important for future generations, but that utilities and cities want to know their vendors and suppliers are dedicated to social responsibility. To demonstrate its commitment, Trilliant is a participating member of the UN Global Compact. The compact is a global call to action for companies to support the UN’s social development goals (SDGs). Trilliant is focused on four of those goals, which continue to guide the company’s strategy and align with its mission: affordable and clean energy; sustainable cities and communities; responsible consumption and production; and climate action.
“Our commitment to sustainability in our work has never been clearer,” said Andy White, Chairman and CEO, Trilliant. “Our certifications and awards enable Trilliant to be accountable and ensure that our goals and practices have a positive impact on our customers, partners and all our stakeholders. We’re also proud of our global team members who are energized to engage on initiatives that are aligned with the UN SDGs.”
As the company looks ahead, it has engaged COESIO — third-party sustainability experts — to finalize and support the implementation of Trilliant's Net Zero plan. Trilliant will share its progress and impact in a future update.
About Trilliant
Trilliant® empowers the global energy industry with the only device-agnostic communications platform that enables utilities and cities to deploy any application securely and reliably on one powerful network. Our purpose-built portfolio is designed to offer the power of choice, without risk of customers being “locked in” with one technology provider or meter manufacturer. We are proud to offer mission-critical solutions that support AMI, Data & Analytics, Smart Metering, Smart Grids and Smart Cities. Customers worldwide benefit from Trilliant’s unique combination of flexibility, sustainability and scalability that connects utilities and cities to the IIoT and a more strategic path to the Energy Transition. Visit us at www.trilliant.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230827921449/en/
Contact information
Tracey Mitchell
tracey.mitchell@trilliant.com
Cindy Watson/Anita Wong
StrategicAmpersand
TrilliantPR@stratamp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
